AbbVie Aktie News

AbbVie's third-quarter results were pretty strong, and the company increased its guidance. It was not enough to impress the market, which apparently expected more from the drugmaker.

AbbVie is a Dividend King with a bright future. Enbridge offers an especially dependable dividend.

AbbVie Inc. ( ABBV ) 7th Annual Healthcare Symposium November 14, 2025 11:55 AM EST Company Participants Michael Paas Conference Call Participants Elena Meng Michelle Kehily Stephen Morse Magdalena Sobieszczyk Presentation Operator Okay, everyone, if we can wrap up our conversations so that we can get started and come to the main room. So our final panel today is about vaccines.

As a leader in migraine treatment, AbbVie is committed to addressing the impact of migraine in the workplace. 2025 honorees represent a diverse group of achievers—from teachers and authors to small business owners and aspiring yoga and meditation instructors—each redefining success while living with migraine.

The stock futures are trading lower on Thursday, following another incredible day for the Dow Jones Industrials, while the rotation out of the NASDAQ and into technology is still gaining traction.

These companies have exceptional dividend track records. AbbVie is moving on from its Humira patent losses, and its portfolio benefits from some exceptionally profitable products.

PARMA, Italy, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Chiesi Group today announced it has entered into an exclusive license agreement with Aliada Therapeutics, a wholly owned subsidiary of AbbVie, to advance blood-brain barrier (BBB)-crossing platform technology in lysosomal storage disorders (LSD) to address challenging disease areas with high unmet need.

- A total of 17 abstracts, including three accepted for presentation in the Cosmetic "Top Ten" Session, underscore Allergan Aesthetics' global industry leadership across multiple aesthetic categories - Oral abstract presentations include Phase 3 clinical study results for first-in-class botulinum neurotoxin serotype E (trenibotulinumtoxinE) and results from a Phase 4 study evaluating natural ou...